Ilmoitus osakkeiden siirtymisestä Desentum Oy:n osakkeenomistajalle

by kati.sallinen@desentum.fi | Sep 26, 2024 | News

Desentum Oy:n (“Yhtiö”) yhtiöjärjestyksen 9 §:n mukaisesti osakkeenomistajille ilmoitetaan, että Suida Invest Oy on 23.9.2024 myynyt 14240 A-osaketta (“Osakkeet”) STO-Rahoitus Oy:lle 2,00 euron osakekohtaiseen hintaan. Osakkeiden siirtymisestä...

Pekka Mattila conferred as Honorary Doctor at the University of Eastern Finland

by kati.sallinen@desentum.fi | Jun 10, 2024 | News

Pekka Mattila, CEO of Desentum was conferred as Honorary Doctor at the University of Eastern Finland on Jun 7, 2024. The Faculty of Science, Forestry and Technology stated the following: “In 2011, Pekka Mattila and researchers from the Department of Chemistry at the...

Kutsu Desentum Oy:n varsinaiseen yhtiökokoukseen / Summons to Annual General Meeting of Desentum Oy

by kati.sallinen@desentum.fi | May 29, 2024 | News

Desentum Oy:n osakkeenomistajat kutsutaan yhtiön varsinaiseen yhtiökokoukseen, joka pidetään 17.6.2024 klo 14:00 alkaen osoitteessa Technopolis, Innopoli 2, Tekniikantie 14, 02150 Espoo. Kokoushuone: Edison 2. Yhtiökokousta voi seurata Zoom-etäyhteyden kautta. Ohjeet...

Desentum raised 12 million euros for advancing allergy vaccine development

by raikeeoy | Feb 8, 2024 | News

Desentum, a Finnish biopharmaceutical company with its birch pollen allergy vaccine candidate DM-101PX currently being tested in a clinical study in Canada, raised 12 M€ in a funding round arranged by an investment service company Springvest Oyj. Desentum intends to...

Desentum announces full recruitment of a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy

by kapu@raikee.fi | Nov 27, 2023 | News

Desentum announces today that DM-101-C-002, a clinical study evaluating safety and tolerability of the investigational birch pollen allergy vaccine DM-101PX, has been fully recruited and the dosing of all cohorts has been started. DM-101-C-002 is a randomised,...

First subjects dosed in a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy

by kapu@raikee.fi | Oct 13, 2023 | News

Desentum today announces the dosing of first subjects in a clinical study evaluating safety and tolerability of its investigational birch pollen allergy vaccine DM-101PX. The study, which is conducted in Canada, also assesses the effect of DM-101PX on allergic...